'Adjusted analysis' diaporamas de présentation

FDA Presentation NDA 21-661 RSR13 ( efaproxiral sodium )

FDA Presentation NDA 21-661 RSR13 ( efaproxiral sodium ). Oncology Drug Advisory Committee Meeting May 3, 2004. Chemistry Josephine Jee, Ph.D. Hasmukh Patel, Ph.D. Pharmacology Anwar Goheer, Ph.D. John Leighton, Ph.D. Biopharmaceutics Atul Bhattaram, Ph.D. Joga Gobburu, Ph.D.

684 views • 50 slides

NDA 21-063

NDA 21-063. Oxaliplatin in combination with 5-FU and leucovorin for first line therapy for colorectal cancer.

441 views • 28 slides

PROCESS vs. WA State SCS Study

PROCESS vs. WA State SCS Study. A Comparison of Study Design, Patient Population, and Outcomes August 29,2007.

337 views • 21 slides

Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center

Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center. Implications of Preoperative Thienopyridine Use Prior to Coronary Bypass Graft Surgery in Patients with ACS: A Report from the ACUITY Trial. Disclosures. Sanofi-aventis: Consultant, speaker

199 views • 19 slides

Use of Arteriotomy Closure Devices and the Risk of Vascular Complications: An Analysis of 227,879 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin MD, Sunil V. Rao MD, Tracy Y. Wang MD, MS, David Dai MS, David J. Cohen MD, MSc, Steven P. Marso MD, on behalf of the NCDR

304 views • 18 slides